| Name | Title | Contact Details |
|---|
KCAS Bioanalytical Labs is a Shawnee, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rouge Valley Health System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Rouge Valley Health System is based in Scarborough, ON. You can find more information on Rouge Valley Health System at www.rougevalley.ca
Kramer Group Inc is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Flare Capital Partners invests and specializes exclusively in the healthcare technology sector. Working side-by-side, Flare Capital parlays strengths in business and medicine into action that supports entrepreneurs who provide innovative solutions and strive to be market leaders.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.